Malignant melanoma: Treatments emerging, but early detection is still key

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 7, 2002, Pages 529-545

  Masci, Paul ^a   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL PRODUCT; CANCER VACCINE; DACARBAZINE; INTERLEUKIN 2;

ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEVER; HEREDITY; HIGH RISK POPULATION; HUMAN; MELANOMA; METASTASIS; MYALGIA; NEUROLOGICAL COMPLICATION; PRACTICE GUIDELINE; RISK FACTOR;

EID: 0036064270     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.7.529     Document Type: Article

References (43)

1. Melanoma: Chemoimmunotherapy (biologic and cytotoxic therapies for disseminated disease)
2. Recent trends in cutaneous melanoma incidence among whites in the United States
3. The pathogenesis of melanoma induced by ultraviolet radiation
4. Overview of skin cancer detection and prevention for the primary care physician
5. Common acquired nevomelanocytic nevi and the fourth dimension
6. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J
7. Individuals at high risk for melanoma
8. Dysplastic melanocytic nevi
9. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma
10. Genetic epidemiology of familial melanoma
11. Molecular genetics of familial cutaneous melanoma
12. A cell cycle regulator potentially involved in genesis of many tumor types
13. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
14. Update on familial cancer syndromes and the skin
15. Sorting the hype from the facts in melanoma
16. Melanoma and sun exposure
17. Melanoma
18. What you need to know about moles and dysplastic nevi
19. Who discovers melanoma? Patterns from a population-based survey
20. The histogenesis and biologic behavior of primary human malignant melanomas of the skin
21. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
22. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
23. A new American Joint Committee on Cancer staging system for cutaneous melanoma
24. Primary cutaneous melanoma: Identification of prognostic groups and estimation of individual prognosis for 5093 patients
25. Technical details of intraoperative lymphatic mapping for early stage melanoma
26. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
27. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs
28. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities
29. Lymphatic drainage of skin to a sentinel lymph node in a feline model
30. Technical details of intraoperative lymphatic mapping for early stage melanoma
31. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
32. Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm
33. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): Results of a multi-institutional randomized surgical trial
34. Surgical margins and prognostic factors in patients with thick (> 4 mm) primary melanoma
35. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
36. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
37. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
38. Vaccination for melanoma
39. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the gm2-klh/qs-21 vaccine in patients with resected stage iib-iii melanoma: Results of intergroup trial e1694/s9512/c509801
40. Prognostic factors in metastatic melanoma
41. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up
42. NCCN melanoma practice guidelines. National Comprehensive Cancer Network